Herpes Simplex Virus: Pathogenesis and Therapies

Herpes Simplex Virus (HSV) is a common human pathogen with a global reach, known for its complex life cycle and impact on public health. This comprehensive guide will explore the pathogenesis of HSV, its intricate interactions with the host immune system, and the current therapeutic approaches, including the ongoing efforts in vaccine development. Understanding HSV is crucial for students of biology and medicine, offering insights into viral strategies and the challenges of antiviral interventions.

HSV infections are widespread, with a global seroprevalence of 66%. They are typically caused by two types: HSV-1, usually associated with orofacial lesions, and HSV-2, primarily linked to genital lesions. These viruses silently target mucosa and skin, establishing a lifelong latent infection in neurons. Often, initial infections are asymptomatic, leading to unintentional transmission and making disease control particularly challenging.

Understanding Herpes Simplex Virus: Pathogenesis

The pathogenesis of HSV involves a fascinating interplay between the virus and host cells, encompassing lytic infection, latency, and periodic reactivation. Delving into these stages reveals the virus's sophisticated survival strategies.

Structural and Biological Characteristics of HSV

HSV is a double-stranded, DNA-enveloped virus. Its structure is quite complex:

• DNA core: Enclosed within an icosahedral protein capsid made of 162 capsomeres.
• Tegument: A protein-rich matrix surrounding the capsid, containing crucial proteins like VP16, UL36, and VP22 involved in replication and immune evasion.
• Envelope: A lipid bilayer membrane adorned with 13 branched glycoproteins (gB, gC, gD, gE, gH, gL, gK, gM, gN, gI) vital for viral invasion and immune evasion.

The HSV-1 genome, approximately 150 kilobase pairs (kbp), has recently been found to have 284 open reading frames (ORFs), highlighting its immense genetic complexity. HSV gene expression follows a sequential cascade, categorized into three groups:

• Immediate Early (IE or α) genes: First expressed, regulated by tegument protein VP16. Products like ICP0 and ICP4 are crucial for viral replication and expression of other genes.
• Early (E or β) genes: Include β1 and β2 proteins, mainly responsible for viral nucleic acid metabolism, such as thymidine kinase and DNA polymerase.
• Late (L or λ) genes: Comprise viral structural proteins (glycoproteins, capsid proteins) essential for viral attachment, entry, and antigenicity.

Lytic Infection: How HSV Invades and Replicates

Lytic infection is the active phase where the virus replicates and produces progeny virions, typically in mucosal epithelial cells. This process involves several key steps:

1. Host-cell Entry: Primary infections target mucosal epithelium. HSV enters cells mainly via two pathways:

• Post-attachment fusion: Glycoproteins B and/or C (gB/gC) bind to heparan sulfate proteoglycans (HSPGs) on filopodia, guiding the virus to the cell surface. Viral glycoprotein D (gD) then attaches to specific receptors (Herpesvirus Entry Mediator (HVEM), nectin-1, nectin-2, 3-O-sulfated heparan sulfate). This signals the glycoprotein H-L complex (gH-gL), activating gB to fuse viral and cellular membranes, allowing the capsid into the cytoplasm.
• Endocytosis and phagocytosis-like uptake: HSV binds to gD receptors in the endosome, activating Rho GTPase and rearranging the cytoskeleton, leading to fusion with the endosomal membrane.

2. Genome Expression: After entering the cytoplasm, inner tegument proteins transport the viral capsid along microtubules to the nuclear pore. The viral genome is released into the nucleus and initially silenced by histones and nuclear domain 10 (ND10) bodies. However, outer tegument proteins (VP16, VP22, pUL36) migrate to the nucleus, initiating viral DNA expression. VP16 recruits host factors (HCF1, Oct-1, LSD1) to initiate IE gene transcription. IE protein ICP0 then disrupts silencing by binding to CoREST, displacing HDAC, and degrading ND10 bodies, enabling the transcription of E and L genes. ICP0 also facilitates viral replication by blocking host responses like IRF3 inactivation.
3. Transmission: Progeny virions egress from the host cell via two main pathways:

• Cell-cell spread (CCS): Viral particles are directly delivered to cellular junctions, infecting adjacent cells. This mechanism protects virions from neutralizing antibodies and enhances infection efficiency, often exploiting host adhesion proteins like nectin-1.
• Cell-free release (CFR): Viral particles are released into the extracellular space to infect distant cells. Glycoproteins (gC, gK, gM, gN), tegument proteins (UL11, UL16, VP22), and ICP27 are involved. HSV-1 can also use extracellular vesicles (EVs) for packaging and delivering viral components, including transcription factors like Oct-1, significantly enhancing transmission.

Latent Infection: The Silent Persistence of HSV

While most viruses are cleared, a portion of HSV escapes host immunity to establish latent infection in sensory neurons. HSV-1 commonly resides in the trigeminal ganglion (TG), while HSV-2 typically latently infects the dorsal root ganglia (DRG). Key aspects of latency include:

• Entry into Neurons: HSV-1 attaches at the axon terminus near peripheral epithelial cells or directly enters the cell body. Inner tegument proteins (VP1/2, UL36, Us3) travel with nucleocapsids along nerve fibers to the neuron nucleus. pUL36 protein "hijacks" dyneins and kinesins for transport.
• Establishing Latency: Viral DNA is silenced by histones and histone-modifying enzymes. The absence of HCF1 and VP16 in neuronal nuclei is thought to contribute to this. Host immunity, particularly interferon-inducible protein 16 (IFI16) and immune surveillance by microglia and astrocytes, also plays a role. CD8+ T cells in ganglia are crucial for maintaining latency.
• Latency-Associated Transcripts (LATs): A neuron-specific promoter drives LAT expression, which is crucial for enhancing latency reactivation. LATs produce miRNAs and sncRNAs that suppress key lytic regulatory factors (ICP0, ICP4, ICP34.5) and alter the neuronal environment, preventing apoptosis and suppressing antiviral responses.

Reactivation: The Return of the Virus

Latent HSV can periodically reactivate, especially in immunocompromised individuals. This leads to recurrent herpes, viral shedding, and potential transmission. If the virus reaches the central nervous system (CNS), it can cause encephalitis. Reactivation involves:

• Triggering Stressors: Stress (acute, chronic), fever, UV light, and heat activate the glucocorticoid receptor (GR). GR exerts anti-inflammatory and immunosuppressive effects, mitigating T cell activation and promoting viral gene expression. GR activation directly stimulates viral gene expression, including ICP0, ICP4, ICP27, and VP16.
• Viral Gene Expression: ICP0, normally dormant during latency, becomes expressed, epigenetically regulating the viral genome and promoting replication. It disrupts ND10 structures and dissociates HDACs to relieve repression. VP16 initiates IE gene transcription, which further stimulates E and L gene expression.
• Trophic Support Loss: Reduced nerve growth factor (NGF) can lead to reactivation, as HSV relies on NGF for neurite outgrowth and spread. Anti-NGF antibodies have been shown to increase viral shedding.
• Host Signaling Pathways: Cellular stress, such as activation of the c-Jun signaling pathway, can enhance reactivation potential by influencing latent state adjustments.
• Immune Heterogeneity: The distribution and effectiveness of host immune cells, especially tissue-resident memory CD8+ T cells (TRMs), vary, creating